id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-D-0814-0002,FDA,FDA-2022-D-0814,Infant Formula Transition Plan for Exercise of Enforcement Discretion: Guidance for Industry; Availability,Notice,Notice of Availability,2022-10-06T04:00:00Z,2022,10,2022-10-06T04:00:00Z,,2022-10-06T14:54:44Z,2022-21794,0,0,09000064853c3b60
FDA-2022-D-0814-0003,FDA,FDA-2022-D-0814,Infant Formula Transition Plan for Exercise of Enforcement Discretion: Guidance for Industry,Other,Guidance,2022-10-06T04:00:00Z,2022,10,2022-10-06T04:00:00Z,2022-11-08T04:59:59Z,2024-11-07T00:43:08Z,,1,0,09000064853c9b9a
FDA-2022-D-0814-0001,FDA,FDA-2022-D-0814,Infant Formula Enforcement Discretion Policy: Guidance for Industry,Other,Guidance,2022-05-17T04:00:00Z,2022,5,2022-05-17T04:00:00Z,,2024-11-12T23:40:48Z,,1,0,0900006485084c22